We are a clinical-stage biotechnology company focused on the discovery, research and development of innovative treatments for RASopathies, MAPK pathway-driven tumors, and other diseases, including central nervous system (CNS) disorders. Our Therapeutic Pipeline We are advancing a pipeline of two therapeutic product candidates, with a focus on our lead product candidate, PAS-004, a next-generati…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$21M
▼ -46.9% YoY
Op. Margin
–
ROIC
-43.99%
▲ +11.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$18M
▼ -9.3% YoY
Op. Cash Flow (TTM)
-$18M
▼ -9.3% YoY
Net Debt
-$46M
Net Cash Position
Cash & Equiv.
$46M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with KTTA
Held by ETFs
KTTA is in 1 US ETF. The largest of them, with KTTA's weight in each:
Pasithea Therapeutics (KTTA) in three numbers
Questions about Pasithea Therapeutics
Is Pasithea Therapeutics a high-quality business?
Pasithea Therapeutics scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 3130.4%, and its weakest is return on capital at -44.0%. The Quality tab shows every check against its target.
Does Pasithea Therapeutics (KTTA) pay a dividend?
No. Pasithea Therapeutics (KTTA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 12 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in KTTA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing KTTA
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.